|
KMID : 1128320220200010010
|
|
Electrolytes & Blood Pressure
2022 Volume.20 No. 1 p.10 ~ p.16
|
|
|
Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance
|
|
Park Hayne Cho
Oh Yun-Kyu
|
|
|
Abstract
|
|
|
|
Autosomal dominant polycystic kidney disease is the most common hereditary renal disease affecting more than 13 million people worldwide. Renal function deteriorates as the cysts in both kidneys increase in number and size, which eventually results in end-stage kidney failure. Until recently, conservative management for chronic kidney disease such as blood pressure control, low sodium diet, adequate water intake, and weight control were known for the only treatment of polycystic kidney disease. However, the introduction of disease-modifying drug has led to the new paradigm shift in the management of polycystic kidney disease. Tolvaptan, the vasopressin V2 receptor antagonist, has been introduced to the patients with large kidneys since it can inhibit cyclic adenosine monophosphate, attenuates cyst growth, and delays renal failure. This article reviews the two important practical issues in the management of polycystic kidney disease: blood pressure and water balance. Firstly, the article will review the pathogenesis of high blood pressure in polycystic kidney disease and will demonstrate the current up-to-date management plan for blood pressure control. Secondly, this article will explain the mechanism of Tolvaptan on the treatment of polycystic kidney disease and its possible adverse effect on water and sodium balance.
|
|
|
KEYWORD
|
|
|
Autosomal dominant polycystic kidney disease, Blood pressure, Vasopressin V2 receptor antagonist, Water balance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|